Adaptimmune (ADAP)

Adaptimmune

The time to redefine the treatment of cancer is now.

About Us

Redefining the treatment of solid tumor cancers.

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.

Using a personalized approach that has the potential to radically improve the patient experience.

We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.

A future where a single infusion could reshape cancer care.

We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the  first engineered T-cell therapy in solid tumors to help improve cancer treatment.

SEC Filings

For all investor or media inquiries, visit https://www.adaptimmune.com/contact.

Filing date	Description	Form	Filing Group	View
Jan 21, 2021	Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3	424B5	Registration Statements	0001193125-21-012567.pdf 0001193125-21-012567.rtf 0001193125-21-012567.xls View HTML
Jan 19, 2021	Report of unscheduled material events or corporate event	8-K	Current Reports	0001193125-21-010735.pdf 0001193125-21-010735.rtf 0001193125-21-010735.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Jan 19, 2021	Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3	424B5	Registration Statements	0001193125-21-010752.pdf 0001193125-21-010752.rtf 0001193125-21-010752.xls View HTML
Jan 19, 2021	Registration of up to an additional 20% of securities for any offering registered on a S-3	S-3MEF	Registration Statements	0001193125-21-011747.pdf 0001193125-21-011747.rtf 0001193125-21-011747.xls View HTML
Jan 11, 2021	A statement of beneficial ownership of common stock by certain persons	SC 13G	Other	0000902219-21-000009.pdf 0000902219-21-000009.rtf 0000902219-21-000009.xls View HTML
Dec 23, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	0000899243-20-035009.pdf 0000899243-20-035009.rtf 0000899243-20-035009.xls View HTML
Dec 16, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	0000899243-20-034089.pdf 0000899243-20-034089.rtf 0000899243-20-034089.xls View HTML
Dec 14, 2020	Report of unscheduled material events or corporate event	8-K	Current Reports	0001193125-20-316413.pdf 0001193125-20-316413.rtf 0001193125-20-316413.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Dec 11, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	0000899243-20-033481.pdf 0000899243-20-033481.rtf 0000899243-20-033481.xls View HTML
Dec 11, 2020	Statement of changes in beneficial ownership of securities	4	3,4,5	0000899243-20-033476.pdf 0000899243-20-033476.rtf 0000899243-20-033476.xls View HTML

Data provided by Kaleidoscope.

Adaptimmune (ADAP)

Adaptimmune

The time to redefine the treatment of cancer is now.

About Us

Redefining the treatment of solid tumor cancers.

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.

Using a personalized approach that has the potential to radically improve the patient experience.

We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.

A future where a single infusion could reshape cancer care.

We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the  first engineered T-cell therapy in solid tumors to help improve cancer treatment.